NAMS · NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Gooimeer 2-35, Naarden, 1411 DC, Netherlands
Biotechnology
Healthcare

Market Cap

2.208B

52 Wk Range

$17.90 - $42.20

Previous Close

$19.51

Open

$19.21

Volume

1,745,134

Day Range

$18.28 - $19.78

Enterprise Value

1.58B

Cash

628.2M

Avg Qtr Burn

-39.77M

Insider Ownership

0.89%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026